Bayer sales and marketing update

The U.K.’s NICE issued a final appraisal determination (FAD) recommending the use of Eylea aflibercept from Bayer to treat visual impairment in adults caused by macular edema after branch retinal vein occlusion. The recommendation is contingent on Bayer providing the drug at an undisclosed discount under a patient access scheme. In draft guidance released in June, NICE recommended Eylea for the indication only in patients for whom laser photocoagulation had not been beneficial or was not suitable because of the extent of the hemorrhage. In the FAD, the committee said it concluded that Eylea is “more clinically effective” than laser photocoagulation and that clinical experience suggests the drug is more effective when given before photocoagulation, rather than after. ...